BTIG Reiterates Buy on Apogee Therapeutics, Maintains $137 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.6%

Neg 0% Neu 90.6% Pos 0%

BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $137 price target.

Comments

No comments yet. Be the first!